It is expected that at least one domestic vaccine will be licensed for circulation by the end of the year, according to a report from the Ministry of Health (MoH) presented at a meeting with Deputy Prime Minister Vu Duc Dam on research, technology transfer, clinical trials, Covid-19 medicine, and vaccine production.
After the vaccine manufacturer and research team submitted a complete dossier on the clinical trial and registration of the Nanocovax vaccine, the National Biomedical Research Ethics Council (NBREC) had a meeting to evaluate the results and the Advisory Council will issue a vaccine registration certificate. For the Covivac vaccine, the research team has conducted the second phase trial in northern Thai Binh province.
In addition, MoH has allowed the deployment of phase 2 and phase 3 trials of the ARCT-154 vaccine, the technology for which was transferred from the US, to ensure that there are three clinical trials before December 20.
Experts and scientists note that vaccine production projects in Vietnam are promising and will be put into operation by 2022. Some Vietnamese enterprises are also in the process of negotiating and signing agreements to conduct clinical trials and receive technology transfer for the production of vaccines from abroad.
As regards testing, Vietnamese scientists and businesses have researched, developed, and produced various types of biological kits for rapid testing. However, the production capacity of domestic enterprises is still low, so Vietnam must still import some kits.